Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.
Jeffrey A. Meyerhardt, MD, MPH, FASCO
Advertisement
Articles by Jeffrey A. Meyerhardt, MD, MPH, FASCO
Advertisement
Latest Updated Articles
Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon CancerPublished: August 27th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5